NIPH Clinical Trials Search

UMIN ID: UMIN000001817

Registered date:01/04/2009

Multicenter phase II study of FOLFIRI and bevacizumab as second-line treatment in advanced or recurrent colorectal cancer.

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedColorectal Cancer
Date of first enrollment2009/04/01
Target sample size90
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Patients receive FOLFIRI with bevacizumab (Treatment will be continued unless the disease progression, unacceptable toxicity, or consent withdrawal.)


Primary OutcomeEfficacy: Response rate
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteriaPatient with contraindication to Irinotecan, 5-FU, l-LV, or Bevacizumab.

Related Information


public contact
Name Hirohiko Maeda
Address 3F Ginza-Kobiki Bldg.,16-21,Ginza 7-chome,Chuo-ku,Tokyo,104-0061 Japan Japan
Telephone 03-5550-8962
Affiliation Yakult Honsha Co.,Ltd. Pharmaceutical Development Department, Post Marketing Development Section
scientific contact
Name Kei Muro
Address 1-1 Kanokoden, Chikusa-ku, 464-8681, Nagoya Japan
Telephone 052-762-6111
Affiliation Aichi Cancer Center Department of Clinical Oncology